Lymphoma Archives | Oncotarget

Oncotarget News

Figure 7: B-cell depletion of BTA106 in cynomolgus monkeys.

Novel Therapeutic Bispecific Antibodies for B-cell Lymphoma

April 16, 2024

Our results indicate that IgM-dependent bispecific antibodies are potent therapeutic agents for B-cell malignancies.”BUFFALO, NY- April 16, 2024 – A new research paper was published in Oncotarget's Volume 15 on... read more

Oncotarget

Management of Refractory or Relapsed Classic Hodgkin Lymphoma in Brazil

December 20, 2023

The management of patients with refractory or relapsed CHL in the Brazilian healthcare setting is constrained [...]”BUFFALO, NY- December 20, 2023 – A new review paper was published in Oncotarget's Volume... read more

Figure 6: LP-284 is selectively lethal in cells with TC-NER deficiency. non-Hodgkin's lymphoma

Oncotarget

LP-284 Targets Non-Hodgkin’s Lymphoma and DNA Damage Repair Deficiency

June 12, 2023

we demonstrated the new acylfulvene compound LP-284 has anti-tumor activity including nanomolar potency in fifteen in vitro NHL cell lines and in vivo preclinical NHL models.”BUFFALO, NY- June 12,... read more

Figure 2: Kaplan–Meier curve for estimated median DOR in the DLBCL combined cohort (response-evaluable population).

Oncotarget

Oncotarget | Mivavotinib for Relapsed/Refractory B-cell Lymphoma (Updated)

February 1, 2023

The current analysis provides updated results for these lymphoma patients with extended follow-up.” BUFFALO, NY- February 1, 2023 – A new research paper was published in Oncotarget's Volume 14 on... read more

Figure 3: STRO-001 showed potent cell killing activity on proliferating primary human B cells.

Oncotarget

Oncotarget | Targeting CD74 in B-cell Non-Hodgkin Lymphoma With Antibody-Drug Conjugate STRO-001

January 17, 2023

Taken together, these findings provide a strong rationale for potently and selectively targeting of CD74 in patients with B-NHL [B-cell non-Hodgkin lymphoma].” BUFFALO, NY- January 17, 2023 – A new... read more

Oncotarget

Oncotarget | Combined Epigenetic and Immunotherapy for Blastic and Classical Mantle Cell Lymphoma

December 13, 2022

Here, we describe results using cladribine based combination epigenetic and immunotherapy in MCL [mantle cell lymphoma].”BUFFALO, NY- December 13, 2022 – A new research paper was published in Oncotarget's Volume... read more

Oncotarget

Oncotarget | Mutation Analysis Performed on Tumor Biopsies From Patients With Newly-Diagnosed Germinal Center Aggressive B Cell Lymphomas

November 17, 2022

Our analysis demonstrates that the presence of CREBBP mutations in tumor biopsies from patients with newly-diagnosed GCB DLBCL/HGBL is associated with poorer DFS [disease free survival] following treatment with... read more